Lipella Pharmaceuticals is a clinical-stage biotechnology company developing and commercializing treatments for serious diseases. Our proprietary drug delivery technology has potential applications in addressing diseases of the mucosal tissue including the bladder, urethra, oral cavity, esophagus and colon. We see strong potential for our technology in partnerships and commercial licensing agreements.
Lipella maintains a sterile manufacturing facility in Pittsburgh, PA for the production of clinical supplies and research products.
Click the button above to view Lipella Corporate Presentation
February 2025
Do you have Oral Lichen Planus?
Lipella Pharmaceuticals is testing an investigational mouth rinse for Oral Lichen Planus.
Oral Lichen Planus (OLP) is a chronic inflammatory condition that affects the mucous membranes inside your mouth. It can cause pain, making eating, drinking and even speaking uncomfortable.
We have completed a Phase 2A multi-center dose-escalation clinical trial for our lead product, LP-10, with results published in the peer-reviewed journal International Urology and Nephrology. Our LP-310 program for Oral Lichen Planus has shown positive topline results in its Phase 2a trial. Additionally, we received Orphan Drug Designation for LP-410 in the treatment of oral Graft-versus-Host Disease (GVHD).
We maintain a pipeline of additional product candidates aligned with our strategy of developing proprietary 505(b)(2) assets targeting highly-morbid conditions with no adequate treatments.
Radiation Cystitis Patient Registry
The following is a link to the Radiation Cystitis Patient Registry. If you are a cancer survivor with a history of pelvic radiation therapy, please consider joining the registry.
The potential uses of this registry about radiation cystitis and hemorrhagic cystitis (and cancer survivorship post-radiotherapy) include: improving the scientific understanding of radiation cystitis, discovering trends and common needs of registry participants, describing the aggregate personal characteristics of radiation cystitis patients within the registry, documenting registry patient medical histories, and contacting radiation cystitis registry participants to inform them of new studies. This registry has been created and developed within the published guidance of the National Institute of Health Rare Diseases Registry Program (RaDaR).
Reach Out